Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14079267 | 0.86 | GAA (0.51) | GAACACNA1GALDH1A1POLBNPSR1 | |
| SCHEMBL14079264 | 0.81 | NOTUM (0.47) | GAACACNA1GNPSR1 | |
| SCHEMBL5267462 | 0.73 | CACNA1G (0.77) | CACNA1G | |
| SCHEMBL8245892 | 0.73 | HTR2A (0.51) | ALDH1A1KCNH2 | |
| SCHEMBL917328 | 0.72 | NPSR1 (0.46) | CACNA1GNPSR1 | |
| SCHEMBL28804531 | 0.71 | CACNA1G (0.67) | GAACACNA1GALDH1A1POLBNPSR1 | |
| SCHEMBL16210659 | 0.70 | GAA (1.00) | GAACACNA1GALDH1A1NPSR1 | |
| SCHEMBL8239748 | 0.68 | TAAR1 (0.50) | — | |
| SCHEMBL7682336 | 0.68 | P2RX7 (0.52) | ALDH1A1POLB | |
| SCHEMBL5268034 | 0.67 | CACNA1G (1.00) | GAACACNA1GNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214570-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| US-20060084660-A1 | Psychological disorders; analgesics; Parkinson's disease; antiepileptic agents; irritable bowel disorders; antiarrhythmia agents | NEUROMED TECHNOLOGIES INC. | 2006-04-20 | — | — | US | disclosed |
| US-20040259866-A1 | Calcium channel blockers comprising two benzhydril moieties | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-12-23 | — | — | US | disclosed |
| US-20040209872-A1 | Calcium channel blockers comprising two benzhydril moieties | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209872-A1 | Calcium channel blockers comprising two benzhydril moieties | CACNA1C, CACNA1F, CACNA1D | GAA 1331/4885CACNA1G 5/4885ALDH1A1 1546/4885 |
| US-20080214570-A1 | Therapeutic Agents | NLN, BDNF, GAP43 | GAA 22/4885CACNA1G 1837/4885ALDH1A1 579/4885 |
| US-20060084660-A1 | Psychological disorders; analgesics; Parkinson's disease; antiepileptic agents; irritable bowel disorders; antiarrhythmia agents | CACNA1D, CACNA1E, CACNA1B | GAA 566/4885CACNA1G 14/4885ALDH1A1 903/4885 |
| US-20040259866-A1 | Calcium channel blockers comprising two benzhydril moieties | CACNA1C, CACNA1F, CACNA1D | GAA 1331/4885CACNA1G 5/4885ALDH1A1 1546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.